Read More Best trades on ASH meeting: Kensho Another Celgene partner, Epizyme, is presenting updated data Monday on its leukemia drug. They're among more than 30 external collaborators Celgene has struck deals with in the last six years. "They're on the cutting edge of novel technologies that are evolving to treat cancer better and better," RBC Capital Markets analyst Michael Yee said in a telephone interview. "They're getting their foot in the door early and aligning with these partners, helping fund these programs and getting them off the ground."